Amarin Corp Plc (AMRN)

[ziploc_1]

Tats Mochida agreed, in 2018, to COLLABORATE in the devlopment of new and better EPA meds

Amarin and Mochida Announce Collaboration on Future Development of EPA-based Drug Products and Indications...
June 12, 2018 05:00 ET | Source: Amarin Corporation plc

"BEDMINSTER, N.J. and DUBLIN, Ireland, June 12, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that it has entered into a multi-faceted collaboration with Mochida Pharmaceutical Co., Ltd., an integrated Japanese pharmaceutical company. The collaboration is focused on the development and commercialization of early-stage drug products and indications based on the omega-3 acid, EPA (eicosapentaenoic acid)."

Amarin paid Mochida $2 million,up front, upon completion of this COLLABORATION agreement....The time has come, after the passage of six long years since this agreement was signed...to have Amarin now begin work to bring to the market patented LrR-Et EPA, a med,even superior to their current Vascepa.

I would rather see Amarin spend $50 million on this project rather than on buying back Amarin stock.